# Does Early Administration of Tranexamic Acid Reduce Blood Loss and Perioperative Transfusion Requirement

> **NCT03182751** · PHASE2 · COMPLETED · sponsor: **Mayo Clinic** · enrollment: 128 (actual)

## Conditions studied

- Hip Fractures
- Intertrochanteric Fractures

## Interventions

- **DRUG:** Tranexamic Acid (TXA)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03182751
- **Lead sponsor:** Mayo Clinic
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-04-02
- **Primary completion:** 2022-05-24
- **Final completion:** 2022-05-24
- **Target enrollment:** 128 (ACTUAL)
- **Last updated:** 2023-03-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03182751

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03182751, "Does Early Administration of Tranexamic Acid Reduce Blood Loss and Perioperative Transfusion Requirement". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03182751. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*